AI Article Synopsis
- Erythropoietin (EPO) has been shown to provide neuroprotective benefits in both laboratory and living organisms, particularly against Parkinson's disease induced by MPTP in mice.
- * Researchers demonstrated that injecting EPO-releasing neural precursor cells (Er-NPCs) not only saved dying dopamine neurons in the striatum but also improved mouse behavior through various tests.
- * The positive effects were confirmed with direct EPO injections and were reduced when anti-EPO antibodies were present, suggesting that EPO plays a crucial role in these restorative actions.
Article Abstract
An extensive literature has shown a powerful neuroprotective action of Erythropoietin (EPO) both in vivo and in vitro. This study shows that EPO, whether ectopically administered or released by neural precursors, does reverse MPTP-induced parkinsonism in mice. Unilateral stereotaxic injection of 2.5 × 10 erythropoietin-releasing neural precursor cells (Er-NPCs) rescued degenerating striatal dopaminergic neurons and promoted behavioral recovery as shown by three independent behavioral tests. These effects were replicated through direct intrastriatal administration of recombinant human EPO. At the end of the observational period, most of the transplanted Er-NPCs were vital and migrated via the striatum to reach Substantia Nigra. The restorative effects appear to be mediated by EPO since co-injection of anti-EPO or anti-EPOR antibodies antagonized the positive outcomes. Furthermore, this report supports the neuroprotective action of EPO, which may also be achieved via administration of EPO-releasing cells such as Er-NPCs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.neuropharm.2017.03.035 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!